Sio Gene: Surges on positive follow-up data from gene therapy study

Sio Gene Therapies

16/12/2020 11:03

** Shares of drug developer  SIOX.O  rise 40.5% to $3.99
premarket - set for over two-mth high, if gains hold
    ** SIOX, on Tuesday after market, reported positive
six-month follow-up data from low-dose cohort of its
early-to-mid-stage study of experimental gene therapy for GM1
gangliosidosis  urn:newsml:reuters.com:*:nGNX9rJSVT
    ** Co says initial data from five patients in cohort showed
therapy, AXO-AAV-GM1, was generally well tolerated and had
favorable safety profile 
    ** All five patients demonstrated disease stability at 6
months post treatment - Co
    ** GM1 gangliosidosis is an inherited disorder that
progressively destroys nerve cells in brain and spinal cord
    ** Co earlier this month started high-dose part of
early-to-mid-stage study  urn:newsml:reuters.com:*:nL4N2II3SX
    ** Up to Tuesday's close, stock had fallen 44.5% YTD

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))